Osteoporosis Risk Assessment Instrument (ORAI)
The Osteoporosis Risk Assessment Instrument identifies women at increased risk for low bone mass using age, weight, and estrogen-use status.
Indications for Use
Used to identify postmenopausal women ≥45 years who warrant DXA based on age, low body weight, and lack of estrogen use, with a score ≥9 indicating increased osteoporosis risk that justifies BMD testing. Validated across multiple cohorts with AUC ~0.60–0.84 for detecting DXA‑defined osteoporosis 1 [Level I evidence]; network meta-analysis confirms high sensitivity relative to other tools 2 [Level II evidence].
Insights & Cautions
Identifies more women with low BMD because of high sensitivity, but at the cost of lower specificity (eg, ORAI sensitivity superior to FRAX; specificity significantly lower 1 [Level II evidence]). AUC performance varies widely (0.32–0.84) across 19 cohorts due to heterogeneous thresholds 2 [Level I evidence]. Use only to triage for DXA, not to estimate fracture risk. Less reliable in younger women and diverse populations.